血清P-选择素水平与冠脉病变严重度关系的研究

目的：探讨检测血清P-选择素水平与冠脉病变严重度的关系。方法：70冽冠D病患者，按临床诊断分为2组：急性冠脉综合症组32冽和稳定型冠心病组38例，对照组患者30例。ELISA检测各组患者血清中P-选择素水平．并比较各组间的差异；冠脉造影术对冠脉病变进行Gensini评分，并了解其与血清中P-选择素的相关性。结果：冠心病患者血清中的P-选择素水平显著高于正常对照组；在冠D病组内，急性冠脉综合症组的P-选择素水平显著高于稳定型冠心病患者，但两组冠脉病变Gemini评分无显著差别；而且冠脉病变Gemini评分与血清中P-选择素水平呈明显的相关性。结论：P-选择素可能参与了冠状动脉粥样硬化的发生和发展过程，血清P-选择素水平可能是冠脉病变严重度的一个预测指标。     

Therapeutic effect of 5-FC on YCD modified murine P388 leukemia in vivo

Cytosine deaminases (CDs) in bacteria andfungi are found to deaminate prodrug 5 - FC intocytotoxic agent 5 - FU .Yeast CD (YCD) is clonedfrom Saccharomyces cerevisiae.It has been shownpreviously that YCD was more efficient inconversing5 - FC than bacterial CD(b CD) [1-3 ] .As anovel suicide gene therapy system,YCD/ 5 - Fcsystem may be promising in cancer therapy andprevention of graft versus host disease.In thepresent study,we established a P388/ DBA murineleukemia model by infusin…     

The participation of adenosine receptors in the adenosine 5''-triphosphate-induced relaxation in the isolated rabbit corpus cavernosum penis

AIM: To investigate the participation of adenosine receptors in the adenosine 5'-triphosphate (ATP)-induced relaxation in the corpus cavernosum penis (CCP) of rabbits. METHODS: The ATP-induced relaxation was assessed on the noradrenaline precontracted CCP of rabbits in the presence and absence of 8-(3-chlorostyryl)caffeine (CSC); an adenosine A(2A) receptor antagonist; alloxazine and MRS1754; adenosine A(2B) receptor antagonists; and ARL67156, an inhibitor of ecto-nucleoside triphosphate diphosphohydrolases. RESULTS: Adenosine and ATP relaxed the noradrenaline precontracted CCP of rabbits in a concentration-dependent manner. The adenosine- and ATP-induced relaxations were suppressed by alloxazine and MRS1754, but not by 8-(3-chlorostyryl)caffeine. ARL67156 potentiated the ATP-induced relaxation but not the adenosine-induced one. MRS1754 suppressed the ATP-induced relaxation potentiated by ARL67156. CONCLUSIONS: The above results suggest that, in the CCP of rabbits, the adenosine receptor mediating adenosine-induced relaxation is of the A(2B) receptor and the ATP directly causes relaxation through the A(2B) receptor on the CCP.     

Multiple tachykinin binding sites in peripheral tissues and in brain

Tachykinin binding sites in guinea pig urinary bladder (GPUB), rat salivary gland (RSG), hamster urinary bladder (HUB), rat vas deferens (RVD) and rat cerebral cortex (RCC) were compared using ¹²⁵I-Bolton Hunter conjugates of substance P (¹²⁵I-BHSP), eledoisin (¹²⁵I-BHE) and neurokinin A (¹²⁵I-BHNKA). In typical SP-P tissues (GPUB, RSG) and in RCC, SP was the most potent displacer of ¹²⁵I-BHSP and [Glp⁶, D-Pro⁹]-SP(6–11) was 90 times less active than [Glp⁶, L-Pro⁹]-SP(6–11) while SP methyl ester (SPOMe) was 5–10 times more active than the Bolton Hunter conjugate of SPOMe (I-BHSPOMe). On the other hand, in typical SP-E tissues (HUB, RVD), neurokinin A was most potent in displacing ¹²⁵I-BHE and [Glp⁶,D-Pro⁹]-SP(6–11) was over 300 times more active than [Glp⁶,L-Pro⁹]-SP(6–11) while SPOMe was 160 times less active than I-BHSPOMe. In rat cerebral cortex, the rank order of potency of tachykinins and related analogues in displacing ¹²⁵I-BHE was distinct from that of peripheral SP-E sites, with neurokinin B being the most potent displacer, and SPOMe was over 1 000 times more active than I-BHSPOMe; ¹²⁵I-BHE binding sites in CNS may represent a third category of tachykinin receptor, designated SP-N.     

A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients

Objectives: Previous uncontrolled studies have suggested an interaction between ticlopidine, a major antiplatelet agent, and cyclosporin in heart- and kidney-transplant recipients. The aims of this study were to examine in a randomised, double-blind fashion, the possible interaction between cyclosporin A and ticlopidine (250 mg per day) and the tolerability of this combination in heart-transplant recipients. Methods: Twenty heart-transplant recipients were randomised into either a treated or a placebo group. Blood samples were drawn for time-course evaluation of cyclosporin blood levels over a period of 12 h, following the morning intake of cyclosporin and, for platelet aggregation studies, before and after 14 days of ticlopidine administration. Twenty four-hour urine samples were collected for 6-β-hydroxycortisol measurements, before and after 14 days of ticlopidine. Results: Although given at half the recommended daily dosage, ticlopidine significantly reduced platelet aggregation. Pharmacokinetic parameters indicate that the bioavailability of cyclosporin A was not significantly modified by ticlopidine. However, one patient in the ticlopidine group was withdrawn because of a major fall in cyclosporin blood level within 3 days of treatment. Urinary excretion of 6-β-hydroxycortisol was augmented after treatment in the ticlopidine group compared with the placebo group, suggesting that induction of drug metabolism might have occurred. Data also show quite a large intra-individual variability in cyclosporin bioavailability in the placebo group, suggesting that poor absorption of the drug formulation and/or poor compliance might have contributed to the decreased cyclosporin blood levels in the patient withdrawn from this study and in previous uncontrolled studies. Conclusion: Cyclosporin bioavailability was not clearly modified by a half dosage of ticlopidine in this study. We, however, recommend closely monitoring cyclosporin blood levels when prescribing ticlopidine. Further studies will be needed with new formulations of cyclosporin or when using the full dosage of ticlopidine. Received: 20 July 1996 / Accepted in revised form: 12 February 1997     

P1 blood group antigen expression and epidemic hemolytic uremic syndrome

P1 blood group positivity has been postulated as a host factor which may provide protection against the development of post-enteropathic hemolytic uremic syndrome (HUS). In this study, blood group status in 20 Inuit survivors ofEscherichia coli 0157: H7-associated HUS was compared with age-and sex-matched controls from the same community who had experienced uncomplicated diarrheal illness due to the same pathogen. Of 20 HUS survivors, 6 were P1 antigen positive compared with 8 of the 20 controls (P=0.7). We conclude that P1 antigen positivity was not protective against HUS in this population. Further studies of this condition to clarify the role of host factors in verotoxin-induced endothelial damage are indicated.     

P53蛋白在肾癌中的表达及生物学意义

采用抗Ｐ５３单克隆抗体ＰＡｂ１８０１和微波炉抗原修复法对５３例肾癌、６例错构瘤及６例正常肾组织进行了研究。结果Ｐ５３肾癌中的表达率为５４．７％（２９／５３），在正常肾组织及肾错构瘤中无表达，Ｐ５３蛋白表达与分期、分级有关（Ｐ＜０．０１），而与组织类型、年龄及性别无关，Ｐ５３表达者预后差，说明Ｐ５３可能是判断肾癌生物学行为的一个指标。     

Sources of P300 attenuation after head injury: Single-trial amplitude, latency jitter, and EEG power

Single trial amplitude, latency jitter, and electroencephalographic (EEG) power were examined as sources of the group difference in averaged P300 amplitude among 15 traumatically brain injured and 20 control individuals in an auditory oddball paradigm. Mean amplitude of the individual trials was highly correlated with the amplitude of the averaged P300, with little additional unique variance attributable to latency jitter or EEG power. The group difference in P300 amplitude was also explained by the mean amplitude of the single trials. These results support the robustness of the event-related potential averaging technique within the paradigm used.     

大肠黏膜癌变过程中PTEN和p27的表达及相关性研究

目的 :探讨PTEN及p2 7在大肠黏膜癌变过程中的表达及两者的相关性。方法 :采用免疫组织化学S -P法检测了 5 8例大肠癌 ,15例腺瘤性息肉及 11例配对的癌旁正常组织中抑癌基因PTEN和 p2 7的蛋白表达。分析PTEN和 p2 7的表达情况及与各种临床病理特征的关系及两者的相关性。结果 :在癌旁正常组织、大肠腺瘤性息肉、大肠癌组织中PTEN表达率分别为 (97.3± 4 .3) % ,(85 .2± 16 .8) % ,(13.8± 17.6 ) % ,呈递减趋势。大肠癌DukesA/B期组PTEN蛋白的高表达率为 88.9% ,明显高于DukesC/D期组中的 5 1.6 %。PTEN的高表达率与性别、年龄、肿瘤的大小、部位、分化程度、有无淋巴结转移无关。p2 7主要表达在细胞核 ,也有少量表达在细胞浆。在癌旁正常组织、大肠腺瘤性息肉、大肠癌组织中p2 7高表达率分别为 (98.8± 1.0 8) % ,(86 .0± 13.6 ) % ,(5 6 .8± 2 6 .0 ) % ,呈递减趋势。在大肠癌高、中分化组中 p2 7蛋白的表达率为 71.4 % ,明显高于低分化组中的 2 3.1%。p2 7的高表达率与患者的Dukes分期、性别、年龄、肿瘤的大小、部位及有无淋巴结转移无关。在大肠癌组织中 ,PTEN与 p2 7蛋白的表达呈正相关 (r =0 .6 4 2 )。结论 :PTEN及p2 7表达在癌旁正常组织、大肠腺瘤性息肉、大肠癌组织中均呈递减趋势 ,提示P